An investigation for investors who purchased shares of OvaScience Inc (NASDAQ:OVAS) in the January 2015 secondary offering over potential securities laws violations was announced.
Investors who purchased shares of OvaScience Inc (NASDAQ:OVAS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of OvaScience Inc (NASDAQ:OVAS) concerning whether certain statements in connection with the Secondary Offering were materially false and misleading at the time they were made.
On January 8, 2015, OvaScience Inc conducted a Secondary Offering (the “Offering”), selling 2.3 million shares of the Company’s common stock at $50 per share.
On March 26, 2015, OvaScience Inc announced that presentations by fertility specialists offering the Company’s AUGMENTSM fertility treatment reported encouraging pregnancy rates in women who previously failed multiple cycles of in vitro fertilization (IVF). OvaScience Inc said that Clinical reports from two international IVF clinics will be featured at the Society for Reproductive Investigation (SRI) 62nd Annual Scientific Meeting.
On Mar. 28, 2015, OvaScience Inc announced that additional clinical experience of the Company’s AUGMENTSM treatment demonstrated improved pregnancy rates in women who had failed three to seven prior in vitro fertilization (IVF) cycles. OvaScience Inc said that these results were reported at the Society for Reproductive Investigation (SRI) 62nd Annual Scientific Meeting being held in San Francisco, CA.
Those who purchased shares of OvaScience Inc (NASDAQ:OVAS) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
Leave Your Comments